Sterotherapeutics, a leading biopharmaceutical company dedicated to advancing innovative therapies, is announcing the launch of a Phase 2 clinical trial for ST-002, a novel drug candidate for patients ...
Data confirms Versamune ® HPV has potential as a broadly effective treatment of HPV16-associated cancers - Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025 ...
While main results from a platform study of four experimental drugs for amyotrophic lateral sclerosis are negative, it shows ...
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase” or "Company”), today announced the appointment of two pharma ...
Reducing glucocorticoid use in the treatment of giant cell arteritis and polymyalgia rheumatica — due to the steroid’s host ...
COURTESY UH CANCER CENTER The Queen’s Health Systems and University of Hawaii Cancer Center will develop an oncology clinic at the UH John A. Burns School of Medicine in Kakaako. 1 /3 COURTESY UH ...
Nuvalent (NASDAQ:NUVL – Get Free Report) is anticipated to release its earnings data on Tuesday, February 25th. Analysts ...
2h
Phase 1b Study receives lead clinical site approval KELOWNA, BC / ACCESS Newswire / February 24, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria") ...
Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies ...
Alector (NASDAQ:ALEC – Get Free Report) is anticipated to post its quarterly earnings results after the market closes on ...
ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)——FY 2025 ORLADEYO ...
Actinogen Medical Ltd (ASX:ACW) said its net loss after tax for the six months to December 2024 decreased by 29% to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback